These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18753204)

  • 1. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.
    Youn JW; Hu YW; Tricoche N; Pfahler W; Shata MT; Dreux M; Cosset FL; Folgori A; Lee DH; Brotman B; Prince AM
    J Virol; 2008 Nov; 82(21):10896-905. PubMed ID: 18753204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.
    Rollier C; Depla E; Drexhage JA; Verschoor EJ; Verstrepen BE; Fatmi A; Brinster C; Fournillier A; Whelan JA; Whelan M; Jacobs D; Maertens G; Inchauspé G; Heeney JL
    J Virol; 2004 Jan; 78(1):187-96. PubMed ID: 14671100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse.
    Eisenbach C; Freyse A; Lupu CM; Weigand K; Ernst E; Hoyler B; Stremmel W; Bugert JJ; Encke J
    Vaccine; 2006 Jun; 24(24):5140-8. PubMed ID: 16713033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques.
    Wen B; Deng Y; Chen H; Guan J; Chuai X; Ruan L; Kong W; Tan W
    Mol Ther; 2013 Sep; 21(9):1787-95. PubMed ID: 23774793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice.
    Pancholi P; Perkus M; Tricoche N; Liu Q; Prince AM
    J Virol; 2003 Jan; 77(1):382-90. PubMed ID: 12477843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee.
    Youn JW; Park SH; Lavillette D; Cosset FL; Yang SH; Lee CG; Jin HT; Kim CM; Shata MT; Lee DH; Pfahler W; Prince AM; Sung YC
    Hepatology; 2005 Dec; 42(6):1429-36. PubMed ID: 16317673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.
    Folgori A; Capone S; Ruggeri L; Meola A; Sporeno E; Ercole BB; Pezzanera M; Tafi R; Arcuri M; Fattori E; Lahm A; Luzzago A; Vitelli A; Colloca S; Cortese R; Nicosia A
    Nat Med; 2006 Feb; 12(2):190-7. PubMed ID: 16462801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model.
    Prince AM; Brotman B; Lee DH; Pfahler W; Tricoche N; Andrus L; Shata MT
    J Infect Dis; 2005 Nov; 192(10):1701-9. PubMed ID: 16235167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.
    Elmowalid GA; Qiao M; Jeong SH; Borg BB; Baumert TF; Sapp RK; Hu Z; Murthy K; Liang TJ
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8427-32. PubMed ID: 17485666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation.
    Zubkova I; Choi YH; Chang E; Pirollo K; Uren T; Watanabe H; Wells F; Kachko A; Krawczynski K; Major ME
    Vaccine; 2009 Apr; 27(19):2594-602. PubMed ID: 19428866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.
    Barth H; Rybczynska J; Patient R; Choi Y; Sapp RK; Baumert TF; Krawczynski K; Liang TJ
    Hepatology; 2011 Oct; 54(4):1135-48. PubMed ID: 21674561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.
    Dahari H; Feinstone SM; Major ME
    Gastroenterology; 2010 Sep; 139(3):965-74. PubMed ID: 20621699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.
    Park SH; Shin EC; Capone S; Caggiari L; De Re V; Nicosia A; Folgori A; Rehermann B
    Gastroenterology; 2012 Oct; 143(4):1048-60.e4. PubMed ID: 22705008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
    Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.
    Shata MT; Tricoche N; Perkus M; Tom D; Brotman B; McCormack P; Pfahler W; Lee DH; Tobler LH; Busch M; Prince AM
    Virology; 2003 Sep; 314(2):601-16. PubMed ID: 14554088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection.
    Murata K; Lechmann M; Qiao M; Gunji T; Alter HJ; Liang TJ
    Proc Natl Acad Sci U S A; 2003 May; 100(11):6753-8. PubMed ID: 12748380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.